{
    "nct_id": "NCT06091254",
    "official_title": "A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)",
    "inclusion_criteria": "1. Diagnosis of Cluster of Differentiation 20^+ (CD20^+) FL Grade 1-3a, stage II bulky or stage III / IV\n2. Need for treatment as described in the protocol\n3. Have measurable disease on cross-sectional imaging documented by diagnostic imaging Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n5. Adequate bone marrow function and hepatic function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Central Nervous System (CNS) lymphoma or leptomeningeal lymphoma\n2. Histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma\n3. Waldenstr√∂m Macroglobulinemia (WM, lymphoplasmacytic lymphoma), Grade 3b follicular lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma\n4. Treatment with any systemic anti-lymphoma therapy\n5. Infections and allergy/hypersensitivity to study drug or excipient\n\nNOTE: Other protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": "Key"
}